Eun-Jung Shim1, Jong Won Lee2, Jihyoung Cho3, Hong Kyu Jung4, Nam Hyoung Kim5, Jung Eun Lee6, Junwon Min7, Woo Chul Noh8, Sung-Hwan Park9, Yoo Seok Kim10. 1. Department of Psychology, Pusan National University, Busan, Republic of Korea. 2. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 3. Department of Surgery, Keimyung University School of Medicine, Daegu, Republic of Korea. 4. Department of Surgery, Seran General Hospital, Seoul, Republic of Korea. 5. Department of Advertising and Branding, Kaywon University of Art and Design, Uiwang-si, Gyeonggi-Do, Republic of Korea. 6. Department of Food and Nutrition, Seoul National University, Seoul, Republic of Korea. 7. Department of Surgery, Dankook University College of Medicine, Cheonan, Republic of Korea. 8. Department of Surgery, Korea Institute of Radiology and Medical Science, Korea Cancer Center Hospital, Seoul, Republic of Korea. 9. Department of Surgery, Daegu Catholic University Medical Center, Daegu, Republic of Korea. 10. Department of Surgery, Chosun University College of Medicine, 365 Pilmun-daero, Dong-gu, Gwangju, 61453, Republic of Korea. quintet64@naver.com.
Abstract
PURPOSE: To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS: Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 patients diagnosed with breast cancer between 2007 and 2014, 20,870 patients diagnosed with depression or anxiety disorder one year before breast cancer diagnosis were excluded. Thus, data of 124,381 patients were included in this study. RESULTS: Depression and anxiety disorder were associated with an increased risk of mortality [Hazard Ratio (HR) 1.26, 95% CI 1.18-1.36; HR 1.14, 95% CI 1.08-1.22, respectively] and their co-occurrence further increased the risk (HR = 1.38, 95% CI 1.24-1.54). Antidepressant treatment was related to a reduced risk of mortality. Compared to patients without any psychiatric comorbidity with no antidepressant treatment, the mortality risk increased in patients with either psychiatric comorbidity or both, but the risk seemed to attenuate with antidepressant treatments. CONCLUSION: The current findings suggest that psychiatric comorbidities are markers of increased mortality risk in patients with breast cancer, and antidepressant treatment may attenuate the risk. This underscores the need for screening and treating depression and anxiety disorders to improve survival in patients with breast cancer.
PURPOSE: To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS: Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 patients diagnosed with breast cancer between 2007 and 2014, 20,870 patients diagnosed with depression or anxiety disorder one year before breast cancer diagnosis were excluded. Thus, data of 124,381 patients were included in this study. RESULTS: Depression and anxiety disorder were associated with an increased risk of mortality [Hazard Ratio (HR) 1.26, 95% CI 1.18-1.36; HR 1.14, 95% CI 1.08-1.22, respectively] and their co-occurrence further increased the risk (HR = 1.38, 95% CI 1.24-1.54). Antidepressant treatment was related to a reduced risk of mortality. Compared to patients without any psychiatric comorbidity with no antidepressant treatment, the mortality risk increased in patients with either psychiatric comorbidity or both, but the risk seemed to attenuate with antidepressant treatments. CONCLUSION: The current findings suggest that psychiatric comorbidities are markers of increased mortality risk in patients with breast cancer, and antidepressant treatment may attenuate the risk. This underscores the need for screening and treating depression and anxiety disorders to improve survival in patients with breast cancer.
Entities:
Keywords:
Antidepressive agents; Anxiety; Breast cancer; Depression; Mortality
Authors: Matteo Malgaroli; Kristin L Szuhany; Gabriella Riley; Carly D Miron; Jae Hyung Park; Jane Rosenthal; Abraham Chachoua; Marleen Meyers; Naomi M Simon Journal: J Cancer Surviv Date: 2022-02-28 Impact factor: 4.442
Authors: Xuan Wang; Neng Wang; Linda L D Zhong; Kexin Su; Shengqi Wang; Yifeng Zheng; Bowen Yang; Juping Zhang; Bo Pan; Wei Yang; Zhiyu Wang Journal: Front Oncol Date: 2022-05-10 Impact factor: 5.738
Authors: Francisco José Sánchez-Torralvo; Victoria Contreras-Bolívar; María Ruiz-Vico; José Abuín-Fernández; Inmaculada González-Almendros; Manuel Barrios; Gabriel Olveira Journal: Support Care Cancer Date: 2021-09-21 Impact factor: 3.359